Chinese Journal of Pharmacovigilance ›› 2022, Vol. 19 ›› Issue (8): 857-861.
DOI: 10.19803/j.1672-8629.2022.08.09

Previous Articles     Next Articles

The medication of Breviscapine injection in the treatment of angina pectoris in the real world

ZHANG Lei1, LI Yuanyuan1#, XIE Yanming1*, WANG Lianxin1, YANG Xiaochen2   

  1. 1Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China;
    2School of Statistics, Renmin University of China, Beijing 100872, China
  • Received:2022-02-28 Online:2022-08-15 Published:2022-08-15

Abstract: Objective To explore the correlation of therapeutic effect and dosage of Breviscapine injection in the treatment of angina pectoris in the real world so as to provide reference for clinical use. Methods The clinical data on 2 181 patients treated with Breviscapine injection in the treatment of angina pectoris from 37 big hospitals in China between May 20, 2002 and November 8, 2019 was analyzed based on the hospital information system(HIS). The software of SAS 9.2 was used to process data first and SPSS Clementine 21.0 was used to analyze the correlation of therapeutic effect and dosage. Results Among the 2 181 patients, most of them were elderly patients who mostly have comorbidities with essential hypertension. Among the 3 174 cases of intravenous administration, 2 009 cases (63.30%) of the doses beyond the instructions were used. The top three drug combinations were listed in order of frequency: aspirin, metoprolol and amlodipine, which were commonly used drugs for the treatment of angina pectoris. 1 569 patients had effective outcome indicators. Analysis of the relationship between the dosage and therapeutic effect showed that within the range of the prescribed dosage, the cure rate and recovery rate of 50 mg were higher. At the off-label dosage, the cure rate and recovery rate of 100 mg were higher. The results of chi-square test and regression analysis showed that the effect of the control group better than breviscapine injection when dealing with angina pectoris. Conclusion Clinical treatment should adhere to the principle of safe drug use and rational drug use under standardized guidance. The drug combination of Breviscapine injection in the treatment of angina pectoris could help to improve the clinical benefit. It will works better when administered intravenously at a dose of 50 mg once a day.

Key words: Breviscapine injection, angina pectoris, real world, correlation of therapeutic effect and dosage

CLC Number: